HPV-6- And/or HPV-11- Associated Recurrent Respiratory Papillomatosis for Patients who Previously Received INO-3107

Overview

About this study

The purpose of this study is to evaluate the effiectiveness and tolerability of INO-3107 in subjects with HPV6 and/or HPV-11- associated RRP, who have previously received INO-3107.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Provide written IRB/EC-approved informed consent in accordance with institutional guidelines;
  • Have previously received INO-3107 through participation in the RRP-001 clinical trial..

Exclusion Criteria:

  • As determined by the Investigator, have any medical or psychological or non-medical condition that might interfere with the subject’s ability to participate. 

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 12/13/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

David Lott, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions